PMV Pharmaceuticals, Inc.PMVPNASDAQ
LOADING
|||
Switch Symbol:
R&D Expense Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
-1.03%
↓ 119% below average
Average (26q)
5.45%
Historical baseline
Range
High:32.80%
Low:-18.76%
Volatility
946.3%
High variability
| Period | Value |
|---|---|
| Q3 2025 | -1.03% |
| Q2 2025 | 5.32% |
| Q1 2025 | 26.69% |
| Q4 2024 | -18.76% |
| Q3 2024 | 18.88% |
| Q2 2024 | 11.17% |
| Q1 2024 | -1.53% |
| Q4 2023 | -4.14% |
| Q3 2023 | -1.86% |
| Q2 2023 | -8.16% |
| Q1 2023 | 0.32% |
| Q4 2022 | 9.94% |
| Q3 2022 | 19.23% |
| Q2 2022 | -3.16% |
| Q1 2022 | -2.72% |
| Q4 2021 | 32.80% |
| Q3 2021 | 19.55% |
| Q2 2021 | 2.19% |
| Q1 2021 | 21.34% |
| Q4 2020 | 3.15% |
| Q3 2020 | 3.24% |
| Q2 2020 | -2.54% |
| Q1 2020 | 4.49% |
| Q4 2019 | 16.42% |
| Q3 2019 | -3.69% |
| Q2 2019 | 0.00% |
| Q1 2019 | 0.00% |